JP7437495B2 - ヒトインテグリンα４β７の阻害 - Google Patents

ヒトインテグリンα４β７の阻害 Download PDF

Info

Publication number
JP7437495B2
JP7437495B2 JP2022523102A JP2022523102A JP7437495B2 JP 7437495 B2 JP7437495 B2 JP 7437495B2 JP 2022523102 A JP2022523102 A JP 2022523102A JP 2022523102 A JP2022523102 A JP 2022523102A JP 7437495 B2 JP7437495 B2 JP 7437495B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
alkoxy
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022523102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500437A (ja
JP2023500437A5 (enExample
Inventor
ジー． バーサヴィッチ，マシュー
クイ，ダン
イー． ダウリング，ジェームズ
エヌ． ハーン，クリストファー
エー． ハリソン，ブライス
リン，フー－ヤン
エス． リッパ，ブレイズ
エヌ． ロジャース，ブルース
エム． トロースト，ドーン
ジョン，チェン
ディー． コンゼ，カイル
アイ． ゲラシュト，アレクセイ
キム，ビュンチャン
ラフィ，サルマ
デイ，タイラー
ヒッキー，ユージーン
ホウアン，エヴリン
ザーラー，ロバート
Original Assignee
モーフィック セラピューティック，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モーフィック セラピューティック，インコーポレイテッド filed Critical モーフィック セラピューティック，インコーポレイテッド
Publication of JP2023500437A publication Critical patent/JP2023500437A/ja
Publication of JP2023500437A5 publication Critical patent/JP2023500437A5/ja
Priority to JP2024018866A priority Critical patent/JP7702004B2/ja
Application granted granted Critical
Publication of JP7437495B2 publication Critical patent/JP7437495B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)
JP2022523102A 2019-10-16 2020-10-16 ヒトインテグリンα４β７の阻害 Active JP7437495B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024018866A JP7702004B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリンα４β７の阻害

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16
US62/916,062 2019-10-16
PCT/US2020/055986 WO2021076890A1 (en) 2019-10-16 2020-10-16 INHIBITING HUMAN INTEGRIN α4β7

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024018866A Division JP7702004B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリンα４β７の阻害

Publications (3)

Publication Number Publication Date
JP2023500437A JP2023500437A (ja) 2023-01-06
JP2023500437A5 JP2023500437A5 (enExample) 2023-04-03
JP7437495B2 true JP7437495B2 (ja) 2024-02-22

Family

ID=73198501

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2022523102A Active JP7437495B2 (ja) 2019-10-16 2020-10-16 ヒトインテグリンα４β７の阻害
JP2022509595A Active JP7437490B2 (ja) 2019-10-16 2020-10-16 ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
JP2021576053A Active JP7209116B2 (ja) 2019-10-16 2021-10-15 ヒトインテグリンα４β７の阻害
JP2023000761A Active JP7500785B2 (ja) 2019-10-16 2023-01-06 ヒトインテグリンα４β７の阻害
JP2024018765A Active JP7717202B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
JP2024018866A Active JP7702004B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリンα４β７の阻害
JP2024091304A Pending JP2024116230A (ja) 2019-10-16 2024-06-05 ヒトインテグリンα４β７の阻害

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2022509595A Active JP7437490B2 (ja) 2019-10-16 2020-10-16 ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
JP2021576053A Active JP7209116B2 (ja) 2019-10-16 2021-10-15 ヒトインテグリンα４β７の阻害
JP2023000761A Active JP7500785B2 (ja) 2019-10-16 2023-01-06 ヒトインテグリンα４β７の阻害
JP2024018765A Active JP7717202B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
JP2024018866A Active JP7702004B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリンα４β７の阻害
JP2024091304A Pending JP2024116230A (ja) 2019-10-16 2024-06-05 ヒトインテグリンα４β７の阻害

Country Status (37)

Country Link
US (3) US11104661B1 (enExample)
EP (3) EP4045039B1 (enExample)
JP (7) JP7437495B2 (enExample)
KR (2) KR20220102669A (enExample)
CN (3) CN119192137A (enExample)
AR (1) AR120244A1 (enExample)
AU (2) AU2020366435A1 (enExample)
BR (1) BR112022007284A2 (enExample)
CA (1) CA3154269A1 (enExample)
CL (1) CL2022000959A1 (enExample)
CO (1) CO2022005759A2 (enExample)
CR (1) CR20220205A (enExample)
CU (1) CU20220027A7 (enExample)
DK (1) DK4045039T3 (enExample)
DO (2) DOP2022000081A (enExample)
EC (1) ECSP22038978A (enExample)
ES (1) ES3035561T3 (enExample)
FI (1) FI4045039T3 (enExample)
HR (1) HRP20250749T1 (enExample)
HU (1) HUE071814T2 (enExample)
IL (2) IL319053A (enExample)
LT (1) LT4045039T (enExample)
MA (1) MA57399B1 (enExample)
MD (1) MD4045039T2 (enExample)
MX (1) MX2022004406A (enExample)
PE (1) PE20221829A1 (enExample)
PH (1) PH12022550886A1 (enExample)
PL (1) PL4045039T3 (enExample)
PT (1) PT4045039T (enExample)
PY (1) PY2065718A (enExample)
RS (1) RS66976B1 (enExample)
SI (1) SI4045039T1 (enExample)
TW (7) TWI802477B (enExample)
UA (1) UA130059C2 (enExample)
UY (1) UY38926A (enExample)
WO (3) WO2021076890A1 (enExample)
ZA (2) ZA202203872B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024054296A (ja) * 2019-10-16 2024-04-16 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７の阻害

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112312910A (zh) 2018-04-12 2021-02-02 莫菲克医疗股份有限公司 人整合素α4β7拮抗剂
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
US11266643B2 (en) 2019-05-15 2022-03-08 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
CR20220216A (es) 2019-10-16 2023-01-09 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
US20250195485A1 (en) * 2021-12-27 2025-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and medical use thereof
KR20250061759A (ko) 2022-09-09 2025-05-08 시젱 하이스코 파마수티칼 씨오., 엘티디. 프로피온산 유도체 및 이의 의약에서의 응용
WO2024138042A1 (en) 2022-12-22 2024-06-27 Xinthera, Inc. Alpha4 beta7 integrin antagonists and uses thereof
TW202448866A (zh) * 2023-02-21 2024-12-16 英商Ｃ4Ｘ探索有限公司 治療性化合物
IL324720A (en) 2023-05-26 2026-01-01 Adarx Pharmaceuticals Inc SOD1 modulators and methods of using them
WO2025026955A1 (en) * 2023-07-28 2025-02-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2024317579A1 (en) 2023-07-28 2026-02-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof
WO2025176107A1 (zh) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 一种吡啶酮衍生物及其在医药上的应用
CN118702712B (zh) * 2024-07-04 2025-11-11 安徽普利药业有限公司 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法
WO2026018017A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
WO2026018016A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
CN119504796B (zh) * 2024-11-20 2026-03-10 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002544187A (ja) 1999-05-07 2002-12-24 テキサス・バイオテクノロジー・コーポレイシヨン インテグリンのその受容体への結合を阻害するプロパン酸誘導体
JP2021531234A (ja) 2018-04-12 2021-11-18 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
JP2022542184A (ja) 2019-10-16 2022-09-29 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリン（アルファ－４）（ベータ－７）の阻害

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721366A (en) 1993-03-31 1998-02-24 G. D. Searle & Co Platelet aggregation inhibitors
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
CA2268270A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Heterocyclic derivatives as factor xa inhibitors
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
ES2221227T3 (es) 1997-11-24 2004-12-16 MERCK & CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1091945A1 (en) 1998-06-29 2001-04-18 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
AU747784B2 (en) * 1998-07-29 2002-05-23 Merck & Co., Inc. Integrin receptor antagonists
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
ATE364592T1 (de) 1999-09-24 2007-07-15 Genentech Inc Tyrosinderivate
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
PL365729A1 (en) * 2000-08-30 2005-01-10 Pharmacia Corporation Gem-substituted alpha v beta 3 integrin antagonists
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
SI1485127T1 (sl) 2002-02-25 2011-09-30 Elan Pharm Inc Dajanje aktivne snovi za zdravljenje vnetja
WO2006026759A2 (en) 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
DE602006019731D1 (de) 2005-06-09 2011-03-03 Ucb Pharma Sa 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
WO2010091411A1 (en) 2009-02-09 2010-08-12 Glaxosmithkline Llc Piperidinyl cyclic amido antiviral agents
KR20130137688A (ko) 2011-03-31 2013-12-17 제넨테크, 인크. 베타7 인테그린 길항제를 투여하는 방법
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
MA39804A (fr) 2014-03-27 2017-02-01 Hoffmann La Roche Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin
WO2016011940A1 (zh) 2014-07-25 2016-01-28 江苏恒瑞医药股份有限公司 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用
EP3581585A1 (en) * 2014-11-26 2019-12-18 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
EP3978530A1 (en) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
SG11201907820SA (en) * 2017-02-28 2019-09-27 Morphic Therapeutic Inc Inhibitors of (alpha-v)(beta-6) integrin
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
US11179383B2 (en) * 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002544187A (ja) 1999-05-07 2002-12-24 テキサス・バイオテクノロジー・コーポレイシヨン インテグリンのその受容体への結合を阻害するプロパン酸誘導体
JP2021531234A (ja) 2018-04-12 2021-11-18 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
JP2022542184A (ja) 2019-10-16 2022-09-29 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
JP7209116B2 (ja) 2019-10-16 2023-01-19 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７の阻害

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024054296A (ja) * 2019-10-16 2024-04-16 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７の阻害
JP7702004B2 (ja) 2019-10-16 2025-07-02 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７の阻害

Also Published As

Publication number Publication date
MA57399B1 (fr) 2025-06-30
ZA202303992B (en) 2024-06-26
PY2065718A (es) 2023-01-17
DOP2022000081A (es) 2022-07-31
CU20220027A7 (es) 2022-12-12
SI4045039T1 (sl) 2025-07-31
PE20221829A1 (es) 2022-11-29
CN115087444B (zh) 2024-09-17
TWI888065B (zh) 2025-06-21
JP2022548809A (ja) 2022-11-22
AU2020366435A1 (en) 2022-04-21
CA3154269A1 (en) 2021-04-22
ECSP22038978A (es) 2022-06-30
TW202332675A (zh) 2023-08-16
CO2022005759A2 (es) 2022-05-20
FI4045039T3 (fi) 2025-06-20
JP2024054293A (ja) 2024-04-16
JP2023500437A (ja) 2023-01-06
DK4045039T3 (da) 2025-06-30
TW202126624A (zh) 2021-07-16
EP4045039A1 (en) 2022-08-24
US11104661B1 (en) 2021-08-31
KR20230088376A (ko) 2023-06-19
MD4045039T2 (ro) 2025-11-30
JP2024054296A (ja) 2024-04-16
JP2022542184A (ja) 2022-09-29
IL292296A (en) 2022-06-01
AU2021361031A1 (en) 2023-06-08
JP7437490B2 (ja) 2024-02-22
EP4559525A2 (en) 2025-05-28
TWI791304B (zh) 2023-02-01
HRP20250749T1 (hr) 2025-08-15
IL292296B1 (en) 2025-03-01
US20240174632A1 (en) 2024-05-30
MX2022004406A (es) 2022-08-25
IL319053A (en) 2025-04-01
KR20220102669A (ko) 2022-07-20
EP4559525A3 (en) 2025-08-20
TW202500559A (zh) 2025-01-01
TWI900200B (zh) 2025-10-01
WO2021076890A4 (en) 2021-06-10
TWI775182B (zh) 2022-08-21
ZA202203872B (en) 2024-01-31
US11370773B1 (en) 2022-06-28
TW202315868A (zh) 2023-04-16
TW202222793A (zh) 2022-06-16
TWI857592B (zh) 2024-10-01
AR120244A1 (es) 2022-02-09
JP7702004B2 (ja) 2025-07-02
ES3035561T3 (en) 2025-09-04
CR20220205A (es) 2022-07-22
WO2021076890A1 (en) 2021-04-22
CN116783161B (zh) 2026-04-03
BR112022007284A2 (pt) 2022-07-05
RS66976B1 (sr) 2025-07-31
JP2023036958A (ja) 2023-03-14
WO2021076902A1 (en) 2021-04-22
UY38926A (es) 2021-05-31
JP7717202B2 (ja) 2025-08-01
TWI802477B (zh) 2023-05-11
CL2022000959A1 (es) 2023-04-28
EP4228634A1 (en) 2023-08-23
IL292296B2 (en) 2025-07-01
WO2022081983A1 (en) 2022-04-21
CN115087444A (zh) 2022-09-20
LT4045039T (lt) 2025-08-11
TW202500558A (zh) 2025-01-01
HUE071814T2 (hu) 2025-09-28
EP4045039A4 (en) 2023-12-13
EP4228634A4 (en) 2024-12-18
EP4045039B1 (en) 2025-04-23
TW202244040A (zh) 2022-11-16
CN119192137A (zh) 2024-12-27
JP2024116230A (ja) 2024-08-27
CN116783161A (zh) 2023-09-19
PH12022550886A1 (en) 2023-05-03
PL4045039T3 (pl) 2025-09-15
JP7500785B2 (ja) 2024-06-17
TWI840047B (zh) 2024-04-21
JP7209116B2 (ja) 2023-01-19
DOP2025000034A (es) 2025-04-08
UA130059C2 (uk) 2025-10-29
PT4045039T (pt) 2025-07-02

Similar Documents

Publication Publication Date Title
JP7702004B2 (ja) ヒトインテグリンα４β７の阻害
EA052724B1 (ru) ИНГИБИРОВАНИЕ ИНТЕГРИНА ЧЕЛОВЕКА α4β7
OA21139A (en) Inhibiting human integrin ALPHA4BETA7.
WO2022247796A1 (zh) 周期蛋白依赖性激酶9抑制剂的用途

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240209

R150 Certificate of patent or registration of utility model

Ref document number: 7437495

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02